Table 1. Total costs of TB diagnostic tests and market value in the public sector in Brazil, 2012, in USD.
| Diagnostic test | Cost pertest | No. of testsdone inpublic sector | % of totalvolume,public sector | Total value,public sector | % of total value,public sector |
| TST | 5.90 | 725,000 | 33.6% | 4,278,555 | 28.3% |
| IGRA | Not done | Not done | |||
| Sputum smearmicroscopy (ZN) | 2.85 | 1,139,367 | 52.8% | 3,245,596 | 21.5% |
| Culture (liquid) | 31.43 | 91,445 | 4.2% | 2,874,409 | 19.0% |
| Culture (solid) | 16.36 | 168,432 | 7.8% | 2,756,024 | 18.2% |
| Xpert MTB/RIF | 17.80 | 18,000 | 0.8% | 320,400 | 2.1% |
| LPA | Not done | Not done | |||
| PCR | 44.99 | 614 | <0.1% | USD 27,624 | 0.2% |
| First line DST(liquid, SIRE) | 130.54 | 9,049 | 0.4% | USD 1,181,212 | 7.8% |
| First line DST(liquid, SIREP) | 196.65 | 539 | <0.1% | USD 105,995 | 0.7% |
| First line DST(solid, SIRE) | 41.11 | 5,519 | 0.3% | 226,861 | 1.5% |
| Second line DST(liquid, 4 drugs) | 130.54 | 699 | <0.1% | 91,244 | 0.6% |
| Total | 2,158,664 | 100% | 15,107,921 | 100% |
TST = tuberculin skin test; IGRA = Interferon gamma release assay; ZN = Ziehl-Neelsen; LPA = line probe assay; PCR = polymerase chain reaction; DST = drug susceptibility test; SIRE = Streptomycin, Isoniazid, Rifampin, Ethambutol; SIREP = Streptomycin, Isoniazid, Rifampin, Ethambutol, Pyrazinamide; USD = United States Dollars.